Merck Past Earnings Performance
Past criteria checks 4/6
Merck has been growing earnings at an average annual rate of 35.7%, while the Pharmaceuticals industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 17.4% per year. Merck's return on equity is 21.6%, and it has net margins of 15.5%.
Key information
35.7%
Earnings growth rate
35.7%
EPS growth rate
Pharmaceuticals Industry Growth | 20.4% |
Revenue growth rate | 17.4% |
Return on equity | 21.6% |
Net Margin | 15.5% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 1,035,913 | 160,481 | 193,730 | 0 |
30 Jun 23 | 1,023,241 | 147,802 | 194,846 | 0 |
31 Mar 23 | 1,084,164 | 163,535 | 186,562 | 0 |
31 Dec 22 | 1,124,600 | 179,838 | 190,288 | 0 |
30 Sep 22 | 1,147,548 | 163,618 | 202,445 | 0 |
30 Jun 22 | 1,157,128 | 173,520 | 201,562 | 0 |
31 Mar 22 | 1,112,601 | 140,958 | 212,123 | 0 |
31 Dec 21 | 1,064,395 | 131,661 | 208,265 | 0 |
30 Sep 21 | 1,002,110 | 134,624 | 202,942 | 0 |
30 Jun 21 | 879,843 | 121,326 | 200,267 | 0 |
31 Mar 21 | 746,960 | 90,227 | 187,039 | 0 |
31 Dec 20 | 655,847 | 71,902 | 185,489 | 0 |
30 Sep 20 | 686,477 | 116,256 | 180,309 | 0 |
30 Jun 20 | 710,680 | 104,255 | 186,555 | 0 |
31 Mar 20 | 743,720 | 101,692 | 197,113 | 0 |
31 Dec 19 | 744,635 | 78,257 | 198,814 | 0 |
30 Sep 19 | 649,092 | -1,407 | 205,160 | 0 |
30 Jun 19 | 633,302 | 13,257 | 196,327 | 0 |
31 Mar 19 | 633,747 | 28,904 | 181,236 | 0 |
31 Dec 18 | 611,958 | 37,378 | 168,144 | 0 |
30 Sep 18 | 144,570 | -65,656 | 3,343 | 0 |
30 Jun 18 | 270,973 | -40,950 | 51,264 | 0 |
31 Mar 18 | 407,044 | -16,297 | 100,891 | 0 |
31 Dec 17 | 582,002 | 29,455 | 159,209 | 0 |
30 Sep 17 | 1,125,749 | 179,358 | 340,180 | 0 |
30 Jun 17 | 1,063,319 | 157,481 | 326,635 | 0 |
31 Mar 17 | 1,045,176 | 159,314 | 338,090 | 0 |
31 Dec 16 | 1,034,807 | 153,843 | 327,604 | 0 |
30 Sep 16 | 1,036,484 | 146,492 | 336,765 | 0 |
30 Jun 16 | 1,031,758 | 149,614 | 327,199 | 0 |
31 Mar 16 | 1,018,683 | 152,613 | 311,670 | 0 |
31 Dec 15 | 983,446 | 142,545 | 311,514 | 0 |
30 Sep 15 | 976,678 | 155,763 | 302,101 | 0 |
30 Jun 15 | 963,813 | 165,213 | 292,755 | 0 |
31 Mar 15 | 925,146 | 153,964 | 282,312 | 0 |
31 Dec 14 | 863,208 | 151,050 | 264,355 | 0 |
30 Sep 14 | 524,829 | 109,157 | 219,076 | 0 |
30 Jun 14 | 582,779 | 103,945 | 238,253 | 0 |
31 Mar 14 | 657,357 | 112,622 | 248,770 | 0 |
31 Dec 13 | 805,746 | 147,136 | 255,291 | 0 |
30 Sep 13 | 1,118,662 | 156,150 | 303,624 | 0 |
30 Jun 13 | 1,089,157 | 146,407 | 296,464 | 0 |
Quality Earnings: MERK has high quality earnings.
Growing Profit Margin: MERK's current net profit margins (15.5%) are higher than last year (14.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MERK has become profitable over the past 5 years, growing earnings by 35.7% per year.
Accelerating Growth: MERK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MERK had negative earnings growth (-1.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-10.1%).
Return on Equity
High ROE: MERK's Return on Equity (21.6%) is considered high.